Company Description
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases.
Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
The company’s platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors.
Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology.
The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute.
ImmunityBio, Inc. is based in San Diego, California.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 691 |
| CEO | Richard Adcock |
Contact Details
Address: 3530 John Hopkins Court San Diego, California 92121 United States | |
| Phone | 844 696 5235 |
| Website | immunitybio.com |
Stock Details
| Ticker Symbol | IBRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1326110 |
| CUSIP Number | 45256X103 |
| ISIN Number | US45256X1037 |
| Employer ID | 43-1979754 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Richard Gerald Adcock | President, Chief Executive Officer and Director |
| Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.D., M.S., M.Sc. | Founder, Executive Chairman and Global Chief Scientific and Medical Officer |
| David C. Sachs | Chief Financial Officer |
| Dr. Enrique Diloné Ph.D., RAC | Chief Technology Officer |
| Sarah Singleton | Chief Communications Officer and Head of Patient Advocacy |
| Emily Arison | Senior Vice President of Human Resources |
| Dr. Leonard S. Sender M.D. | Chief Medical Officer of Liquid Tumors and Cell Therapy |
| Dr. Sandeep K. Reddy M.D. | Chief Medical Officer |
| Dr. Hans Georg Klingemann M.D., Ph.D. | Chief Science Officer of Cellular |
| Dr. Manju Saxena Ph.D. | Senior Vice President of Product Development and Cell Therapy Program |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 7, 2026 | 10-Q | Quarterly Report |
| May 7, 2026 | 8-K | Current Report |
| Apr 30, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 30, 2026 | ARS | Filing |
| Apr 9, 2026 | 8-K | Current Report |
| Apr 6, 2026 | 8-K | Current Report |
| Mar 31, 2026 | 8-K | Current Report |
| Feb 25, 2026 | SCHEDULE 13D/A | Filing |
| Feb 23, 2026 | 10-K | Annual Report |